Synthesis and Biological Evaluation of 4‑Bromo-N,N-dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development Authors: Elena Bray, Grant C. Glatfelter, Alexander D. Maitland, Nicholas R. Gonzalez, Donna Walther, Jeanine Yacoub, Michael H. Baumann, Jacqueline L. von Salm Published: 2026 ABSTRACT The ongoing psychedelic renaissance has prompted a renewed search for novel drugs based on modifying existing psychedelic motifs. In this study, a synthesis of 4-bromo-N,N-dimethyltryptamine (4-Br-DMT) was achieved and used as a late-stage intermediate for analog development. Specifically, we were able to synthesize and access novel molecules by forming carbon–carbon bonds at the C4 position using palladium cross-coupling reactions. Using the synthetic route described here will facilitate the rapid development of a library of tryptamines with novel 4-position substitutions to investigate structure–activity relationships (SARs) with serotonergic targets. Furthermore, the pharmacological target profile and biological effects of 4-Br-DMT were compared to the 4-hydroxy-N,N-dimethyltryptamine (psilocin) and nonring-substituted analog, N,N-dimethyltryptamine (DMT). Overall, the data indicate that 4-Br-DMT has a serotonergic profile without psychedelic-like effects in mice but has a reduced safety profile compared to psilocin and DMT. Introduction In recent years, there has been increasing interest in the development of psychedelic compounds as research tools and novel medications. − Naturally occurring psychedelics, such as 4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin, 4-OPO3H-DMT), its active metabolite, 4-hydroxy-N,N-dimethyltryptamine (psilocin, 4-OH-DMT), and the unsubstituted analog, N,N-dimethyltryptamine (DMT), have been used for centuries by native populations around the world for their therapeutic properties, − but it was not until the past century and a half that the pure compounds were isolated and studied in a clinical setting. − Since being characterized, natural products and synthetic derivatives like lysergic acid diethylamide (LSD) have been studied in clinical trials for a variety of indications including but not limited to mood disorders, − substance use disorders (SUDs), ,− and headache disorders. − Psychedelic molecules such as DMT, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), and psilocybin are naturally occurring tryptamines that can be isolated from plants, animals, and fungi (Figure ). Tryptamines are a general class of compounds that include biologically relevant neurotransmitters, like melatonin (5-methoxy-N-acetyltryptamine) and serotonin (5-hydroxytryptamine; 5-HT), which are biosynthesized from tryptophan. , Structurally, these molecules have an indole ring and an alkyl amino chain at carbon three (C3) and typically interact with the central nervous system (CNS) but have peripheral targets too. Serotonin, melatonin, 5-MeO-DMT, bufotenine, and sumatriptan all have substitution at C5. Psilocybin, psilacetin, and psilocin have substitution at C4. DMT and tryptamine are unsubstituted except for the alkyl amino chain at C3. Tryptamine pharmacophore and biologically relevant tryptamines. Due to their biological activity and relevance, tryptamines have been studied for decades; however, 4-substituted analogs have not been well-investigated compared to analogs with substitutions at other positions on the benzene ring because of government scheduling and synthetic challenges. C5, C6, and C7 derivatives have been reported, many of which were used to gain insight into the structure–activity relationships (SARs) between these neurotransmitter-like molecules and 5-HT receptors (5-HTRs). SARs explore the connection between chemical structures and their biological activity. Halogenation at C5, C6, and C7 has been explored in medicinal chemistry due to marine natural products having abundant brominated tryptamines. − Substitution at C5 has been studied due to 5-MeO-DMT and the tryptamine-like “triptan” drugs having a variety of C5-substituted tryptamines. − As a major site of metabolism for DMT, C6 substitution has been investigated, with 6-Fl-DMT gaining a lot of attention. , The 7-position of tryptamines has also been examined in studies comparing basic analogs such as 7-methyl-DMT (7-Me-DMT) to DMT and 5-MeO-DMT. , Notably, research on tryptamines with C4 substitution is lacking compared to other positions on the benzene ring, in part due to legal restrictions as well as synthetic challenges. Synthesis of 4-substituted tryptamines can be done through Speeter–Anthony tryptamine synthesis, , indole building routes, and/or reductive aminations (Figure ). However, these methods can be limited due to functional groups not being compatible with the reaction conditions, unavailable or limited starting materials, and/or low-yielding steps with mixtures of products that can be difficult to separate. Many of the known C4 analogs have been synthesized using these well-known routes. Psilocybin analogs have been developed to circumvent the phosphate ester’s stability issues, with 4-AcO-DMT (4-acetoxy-N,N-dimethyltryptamine) being the first. Various ethers and esters have been synthesized and investigated at C4 as well. , Although an abundance of diversity has been applied to C4 of indole, these cannot be directly translated to the tryptamine scaffold. Basic SAR studies at this position with a phenol or aniline have been reported, but forming carbon–carbon bonds is more elusive at this position. The only known example of carbon–carbon bond formation at C4 of a tryptamine was executed for the synthesis of ergotamine derivatives; the tryptamine synthesized was only an intermediate and not a final product to be studied. Synthetic routes to synthesize 4-substituted tryptamines: (i) Speeter–Anthony tryptamine synthesis; (ii) reductive amination; (iii) indole building. 4-Bromo-N,N-dimethyltryptamine (4-Br-DMT, Figure ) is a known molecule, but little biological data about the compound are available in the literature. − Pharmacologically, it has only been investigated in acetylcholinesterase (AChE) inhibition assays with an estimated IC50 = 82 μM and Ki = 49 μM, along with other bromotryptamines. Aryl halides are significant in drug discovery because of their ability to be transformed into a variety of functional groups through a myriad of synthetic reactions. Their ability to be utilized in divergent syntheses can make them prime candidates for rapid analog development, especially when using the aryl bromide as a late-stage intermediate. Cross-coupling reactions have gained a lot of attention in the past couple of decades in drug discovery due to their ability to create carbon–carbon bonds and to develop many analogs for SAR studies. − Metal-catalyzed cross-coupling reactions have been used to synthesize triptans, psilocybin, and ergotamine derivatives but have not been used to synthesize and study new 4-substituted tryptamines. Structure of 4-Br-DMT. Here, the full synthesis and characterization of 4-Br-DMT are described, providing a new resource for synthetic optimization and expansion at the C4 position of tryptamines. To support the utility of this molecule, two new synthetic analogs utilizing cross-coupling reactions were synthesized and chemically characterized. Our synthetic methods are the first known documentation of intermolecular carbon–carbon bond formation at C4 of tryptamines to develop new C4-substituted tryptamine molecules. These developments could lead to a large library of novel analogs with the ability to introduce new hydrogen bond donors (HBDs) and hydrogen bond acceptors (HBAs) at C4. Furthermore, serotonergic activities both in vitro and in vivo are reported for 4-Br-DMT relative to those of psilocin and DMT to provide further insights into the SARs governing the biological effects of halogenated tryptamines. These data will be useful for future drug discovery and development efforts concerning modification of the C4 position of tryptamine scaffolds. Results and Discussion Synthesis Design When designing syntheses for novel 4-substituted tryptamines, all routes and their advantages and disadvantages should be considered. The Speeter–Anthony route utilizes strong acidic and strong reducing conditions throughout the synthesis, which may not be compatible with a variety of functional groups. Indole-building routes work well for symmetric molecules like in the synthesis of C5-substituted tryptamines (Sumatriptan) but lead to a mixture of products when trying to synthesize C4-indole analogs. Reductive amination reactions are used to install alkyl groups on the tryptamine chain in high yields, but diversity can only be introduced on the nitrogen by using this reaction. Because of these constraints, we wanted to apply versatile cross-coupling reactions to 4-Br-DMT to access new compounds. Suzuki–Miyaura cross-coupling is one of the most commonly used cross-coupling reactions in organic synthesis. These reactions occur between an organohalide and a boronic acid/ester to form carbon–carbon bonds. Aryl and alkyl groups can be used in the Suzuki reaction, making it robust and versatile. Another common metal-catalyzed cross-coupling reaction is the Sonogashira reaction. Sonogashira reactions utilize an aryl halide and a terminal alkyne to form carbon–carbon bonds. Alkynes can be transformed into various functional groups through oxidation and reduction, addition, 3 + 2 cycloadditions, etc. These two synthetic reactions were used as examples for creating carbon–carbon bonds at the 4-position on tryptamines. Synthesis of 4-Br-DMT and Analogs 4-Br-DMT has very few syntheses known, with all of them starting from 4-bromoindole. − All of these syntheses include at least one low-yielding (less than 50% yield) step that is not optimal for scaling up a late-stage intermediate. Initial attempts to synthesize 4-Br-DMT using the Speeter–Anthony route were fruitless because the lithium aluminum hydride reduction was too harsh for the aryl bromide, resulting in hydride insertion between the carbon and bromine (Figure ). Using a modified version of the known syntheses and another synthesis utilizing 4-bromotryptamine, the process gave 4-Br-DMT in excellent yields through 3 steps (Scheme ). This synthesis was also executed on a single-gram scale with moderate yields. Starting out, 4-bromoindole (2) was subjected to acid-catalyzed condensation with 1-dimethylamino-2-nitroethylene. The nitroethylene chain was reduced carefully with lithium aluminum hydride to give 4-bromotryptamine. Finally, the target molecule was synthesized under typical reductive amination conditions to yield the product 4-Br-DMT as the free base (1). Synthesis of 4-Br-DMT aReagents and conditions: (a) 1-(dimethylamino)-2-nitroethylene, TFA, rt, 0.5 h, 97%; (b) LAH, THF, 0 °Creflux, 0.5–1 h, 95% crude; (c) AcOH, NaCNBH3, CH2O, MeOH, 0 °C–rt, 8 h, 88%. Reagents and conditions: (a) 1-(dimethylamino)-2-nitroethylene, TFA, rt, 0.5 h, 97%; (b) LAH, THF, 0 °Creflux, 0.5–1 h, 95% crude; (c) AcOH, NaCNBH3, CH2O, MeOH, 0 °C–rt, 8 h, 88%. Hydride insertion into the C–Br bond. With 4-Br-DMT in hand, Sonogashira coupling reaction conditions were tested on the unprotected tryptamine (Scheme ). To our delight, we were able to convert 4-Br-DMT to the trimethylsilyl-protected alkyne, followed by deprotection with potassium carbonate to give the free alkyne. We were also able to achieve a Suzuki–Miyaura reaction with phenyl boronic acid to show another way to form carbon–carbon bonds at the 4-position (Scheme ). These reactions can be optimized to increase yields by screening different ligands, palladium sources, and bases. The alkyne can be cyclized with an azide source to form a 1,2,3-triazole that has an HBD or substituted nitrogen. Further Suzuki reaction investigations should be done with a diverse group of boronic acids to develop this reaction as a tool to access a vast number of analogs with HBDs and HBAs. Cross-coupling Reaction Examples aReagents and conditions: (a) (i) Pd­(PPh3)4, CuI, TMS-acetylene, NEt3, reflux, 16 h, 75%; (ii) K2CO3, MeOH, rt, 8 h, 91%; (b) Pd2(dba)3, XPhos, K3PO4, PhB­(OH)2, H2O, 1,4-dioxane; 16 h, 32%. Reagents and conditions: (a) (i) Pd­(PPh3)4, CuI, TMS-acetylene, NEt3, reflux, 16 h, 75%; (ii) K2CO3, MeOH, rt, 8 h, 91%; (b) Pd2(dba)3, XPhos, K3PO4, PhB­(OH)2, H2O, 1,4-dioxane; 16 h, 32%. Other cross-coupling reactions can also be investigated with 4-Br-DMT to form carbon–carbon bonds, such as Heck reactions to form alkenes or Negishi reactions using organozinc to form a broad spectrum of carbon–carbon bonds (alkyl, alkenyl, benzyl, allyl). Protection of the indole nitrogen may be necessary for further development of cross-coupling reactions and could be done with Boc anhydride, similar to known triptan chemistry. Competition Binding Profiles at Several 5-HT Receptors To assess the potential serotonergic targets of 4-Br-DMT relative to DMT and psilocin, radioligand binding experiments were conducted in transfected cells that stably express 5-HT receptors (5-HT1, 5-HT2, 5-HT6, and 5-HT7). Results from these experiments show that 4-Br-DMT competes for radioligand binding at all serotonin receptors tested, with K i values (affinity) below 100 nM. The highest affinity targets for 4-Br-DMT were 5-HT7 and 5-HT2B (K i = 3.5 nM and 5.6 nM, respectively). 4-Br-DMT was four times more selective at 5-HT2C and two times more selective at 5-HT1A vs 5-HT2A (K i = 10 and 22 nM, respectively, vs 44 nM) but generally displayed high affinity across 5-HTRs assessed (i.e., <100 nM). When comparing 4-Br-DMT to previously reported values for psilocin and other known tryptamines like DMT, it displayed similar low nanomolar affinities at all the serotonin receptors assessed (Table ). It should be noted that the binding affinities are dependent on radioligands and cell types used; thus, assay conditions as well as tracers are highlighted (Table , Table S1, Table S2), and affinities may vary slightly vs previously reported values. − Overall, it was observed that substitution at the 4-position of DMT has varying effects on serotonin receptor binding inhibition constants. Substitution at the 4-position, bromo or phenol, enhanced affinity at 5-HT2B receptors but not at 5-HT2C receptors. Moreover, 4-position halogenation produced similar affinity values at the 5-HT6 receptor relative to reported values for psilocin. , Notably, the affinity of 4-Br-DMT at 5-HT6 was weaker vs the other tryptamines tested, and 4-Br-DMT displayed the strongest relative affinity for 5-HT7. Overall, 4-Br-DMT competed for binding at various serotonin receptor subtypes with low nanomolar affinities, including 5-HT2A, which is linked to psychedelic-like effects in humans and rodents. Additionally, it also displayed higher affinities for 5-HT1A, 5-HT2C, and 5-HT7 receptors relative to its affinity at 5-HT2A, suggesting that these receptors may play a role in its in vivo pharmacological actions. 1Radioligand Binding Assay, K i (nM) K i (nm)Compound5-HT1A 5-HT2A 5-HT2B 5-HT2C 5-HT6 5-HT7 4-Br-DMT 22445.610823.5DMT 183 18645138134154-OH-DMT 16418081753875aRadioligand reference control compound for each 5-HT receptor: 5-HT1A = [3H]­8-OH-DPAT vs 8-OH-DPAT, 5-HT2A = [3H]­ketanserin vs ketanserin, 5-HT2B = [3H]­mesulergine vs SB 206553, 5-HT2C = [3H]­mesulergine vs RS 102221, 5-HT6 = [3H]­LSD vs serotonin.b5-HT1A = [3H]-WAY100635 vs 8-OH-DPAT, 5-HT2A = [3H]-ketanserin vs clozapine, 5-HT2B = [3H]­LSD vs SB 206553, 5-HT2C = [3H]-mesulergine vs ritanserin, 5-HT6 = [3H]-LSD vs clozapine, 5-HT7a = [3H]-LSD vs clozapine. c5-HT1A = [3H]-OH-DPAT vs methysergide.dValues for psilocin (4-OH-DMT) are previously reported from Glatfelter et al. (2022). Radioligand Binding Assay, K i (nM) Radioligand reference control compound for each 5-HT receptor: 5-HT1A = [3H]­8-OH-DPAT vs 8-OH-DPAT, 5-HT2A = [3H]­ketanserin vs ketanserin, 5-HT2B = [3H]­mesulergine vs SB 206553, 5-HT2C = [3H]­mesulergine vs RS 102221, 5-HT6 = [3H]­LSD vs serotonin. 5-HT1A = [3H]-WAY100635 vs 8-OH-DPAT, 5-HT2A = [3H]-ketanserin vs clozapine, 5-HT2B = [3H]­LSD vs SB 206553, 5-HT2C = [3H]-mesulergine vs ritanserin, 5-HT6 = [3H]-LSD vs clozapine, 5-HT7a = [3H]-LSD vs clozapine. 5-HT1A = [3H]-OH-DPAT vs methysergide. Values for psilocin (4-OH-DMT) are previously reported from Glatfelter et al. (2022). Uptake Inhibition and Release Properties at Monoamine Transporters In addition to serotonin receptor binding screening, the compounds were also assessed for uptake inhibition and release properties at the dopamine, norepinephrine, and serotonin transporters (DAT, NET, and SERT, respectively) in rat brain synaptosomes due to known activities of DMT and psilocin at SERT. , Potency and efficacy values for monoamine transporter assays are shown in Table S3. Cocaine was used as a reference nonselective uptake blocker, and the drug exhibited expected potencies for uptake inhibition at DAT, NET, and SERT (IC50 = 224–293 nM). The test compounds were inactive for blocking the uptake of dopamine at DAT up to 10,000 nM. At NET, weak uptake blockade activity was observed for psilocin (IC50 = 9,596 nM) and DMT (IC50 = 2,956 nM), but 4-Br-DMT was inactive. At SERT, all test compounds were uptake blockers, with 4-Br-DMT exhibiting the highest potency (IC50 = 167 nM), and values for psilocin and DMT were similar to those previously reported. , Given the low to mid-nM potencies observed for uptake inhibition of 4-Br-DMT and comparators at SERT, the release activity of the compounds was also assessed. 3,4-Methylenedioxymethamphetamine (MDMA) was used as the reference comparator in SERT release assays, and it displayed expected potency (EC50 = 72 nM) and efficacy (E max = 105%). 4-Br-DMT and psilocin both exhibited partial efficacies for SERT release (E max = 45 and 53%, respectively), while DMT exhibited potent full-efficacy release (EC50 = 102 nM, E max = 93%), similar to previous studies. Overall, 4-Br-DMT was a potent partial SERT releaser, and this activity likely impacts its effects in vivo. Acute Effects of 4-Br-DMT in Mice Given its affinity at 5-HT2A, 4-Br-DMT was next assessed for acute psychedelic-like activity using the mouse head-twitch response (HTR) paradigm while also simultaneously monitoring body temperature and locomotor activity. The potencies of various serotonergic psychedelic drugs to induce the 5-HT2A-mediated HTR are highly correlated with the doses of the drugs that induce subjective effects in humans, highlighting the predictive validity of the model. Here, C57BL/6J mice received injections of 4-Br-DMT, psilocin, or DMT (0.03–30 mg/kg subcutaneously or s.c.) and acute drug effects were recorded for 30 min, and analyzed using previously reported methods. , Relative to psilocin and DMT, 4-Br-DMT did not induce significant increases in the number of HTRs observed (Figure A–D). Conversely, psilocin and DMT induced increases in the HTR counts of mice treated with 0.3–10 mg/kg and 3–10 mg/kg relative to vehicle controls over the first 10 min post-injection (Figure D), consistent with the psychoactivity of the compounds in humans. ,, The potencies (ED50) for psilocin and DMT to induce HTRs were 0.15 and 2.24 mg/kg, which are similar to previously reported values. , Notably, DMT was seemingly much less efficacious (produced overall less total HTRs) via the s.c. route vs HTR counts observed previously via the intraperitoneal (i.p.) route of administration. The differences in HTR efficacy between routes may be due to potential differences in pharmacokinetic parameters, including drug absorption, distribution, metabolism, or other factors. Across recent studies examining the related analog, 5-MeO-DMT in the HTR paradigm, it seems that the i.p. route produces higher HTR counts overall vs the s.c. route. − However, HTR potency and efficacy for psilocin, psilocybin, and other 4-substituted tryptamines appear similar across s.c. and i.p. routes of administration, ,,− so route differences may be a limited phenomenon observed with specific tryptamines. 4-Br-DMT, psilocin, and DMT all induced hypolocomotor effects (Figure E) and reduced body temperature (Figure F) at the highest doses tested (i.e., 3–30 mg/kg). Of note, only a single mouse was tested at the highest dose of 4-Br-DMT due to observed seizure activity and lethality observed ∼40–50 min after administering this dose. Despite this, all compounds produced serotonin syndrome-like effects, suggesting central activities of the drugs at high doses. It is noteworthy that 4-Br-DMT, psilocin, and DMT all target 5-HT2A in vitro, but only psilocin and DMT induced increases in HTRs. 4-Br-DMT seemingly reaches the brain at high doses but may not be an efficacious 5-HT2A agonist. The present study only examined binding affinities of the test compounds at 5-HT receptors, limiting the ability to make conclusions about the functional activity of the drugs. It is known that both psilocin and DMT are nonselective serotonin receptor agonists, but it is presently unclear what pharmacological efficacy is induced by interactions of 4-Br-DMT with 5-HT2A. Furthermore, 4-Br-DMT competes for binding at several other serotonin receptors (e.g., 5-HT1A and 5-HT2C) and is a SERT uptake blocker, which can counteract the expression of HTRs in some contexts. ,,− Therefore, other receptor and transporter targets may impact expression of the HTR by 4-Br-DMT, if it is, in fact, a 5-HT2A agonist like psilocin, DMT, and other tryptamine psychedelics. Acute dose-related effects of psilocin, DMT, and 4-Br-DMT in mice. Time-course plots (A–C) and dose–response curves (D) for psychedelic-like effects on the HTR. Dose–response curves for total distance traveled (cm, % vehicle; E) and temperature change from baseline (°C; F) over the 30 min session. All values are mean ± SEM for n = 5–6 mice, except for the 30 mg/kg dose of 4-Br-DMT (n = 1 due to lethality post-session, marked with X through the symbol). Asterisks represent statistically significant differences vs vehicle. Controls (0 dose). Given that 4-Br-DMT had appreciable affinity at 5-HT1A and 5-HT2C receptors, these targets may play a role in suppressing psychedelic-like effects in the HTR model. To test whether the lack of HTR activity of 4-Br-DMT was due to activity at 5-HT1A, mice were pretreated 30 min prior with the 5-HT1A antagonist, WAY100635 (3 mg/kg). WAY100635 pretreatment did not reveal latent HTR activity, as has been shown for other tryptamine and lysergamide psychedelics (Figure S2). , Additionally, cotreatment with 3 mg/kg each of WAY100635 and the 5-HT2C antagonist, SB242084, also did not reveal elevations in HTRs or alter other effects of the drug (Figure S2). These data suggest that the activity of 4-Br-DMT at 5-HT1A and 5-HT2C receptors does not suppress the expression of 5-HT2A-mediated HTRs. To clarify why 4-Br-DMT does not induce the HTR under several tested conditions, future studies should examine the metabolism and pharmacokinetics of 4-Br-DMT, as well as its ability to function as a partial agonist or an antagonist in the HTR paradigm. Furthermore, the potent SERT uptake inhibition and partial release properties of 4-Br-DMT may also play a role by facilitating simultaneous activation of various other serotonin receptors that can counteract the HTR or induce serotonin-syndrome-like effects. Overall, negligible HTR increases were observed when administering 4-Br-DMT to mice, similar to the related halogenated tryptamine, 5-bromo-N,N-dimethyltryptamine (5-Br-DMT). Although increases in basal HTRs were not observed over a range of doses, unlike psilocin and DMT, at 30 mg/kg 4-Br-DMT, there was notably seizure-like activity and lethality. Hypothermia and hypolocomotor activity of 4-Br-DMT were observed at high doses, indicating the central activity of the drug. Future studies outside the scope of this paper should examine whether 4-Br-DMT is an agonist or antagonist at 5-HT2A and other identified targets. 5-HT1A and 5-HT2C activities did not seemingly suppress 5-HT2A-mediated HTR. Additionally, assessment of the influence of other serotonin receptor targets (i.e., 5-HT7) or route of administration (i.e., i.p. vs s.c.) on the expression of the HTR by 4-Br-DMT and related compounds would be useful to further evaluate and predict the potential psychoactivity of the drug or related compounds in humans. Conclusion Molecules with the tryptamine pharmacophore continue to attract interest as potential medications for the treatment of CNS disorders. In order to synthesize previously inaccessible 4-substituted tryptamines, 4-Br-DMT was proposed as a great synthetic starting point for exploring the C4 position of the tryptamine scaffold. From this work, we have shown two palladium-catalyzed cross-coupling reaction examples on unprotected tryptamines to form new carbon–carbon bonds. Although 4-Br-DMT is not likely an ideal medication candidate due to observed toxicities at high doses and promiscuous serotonin binding, it reiterates that single-atom changes can have dramatic effects on activity and provides an excellent starting point to access intangible analogues with more selective target profiles. Future work will include obtaining 5-HT functional and monoamine transporter profiles for the other synthesized analogues to further characterize pharmacological efficacies that will guide analog development. With a scalable 3-step synthesis in hand, rapid analog development can be accomplished to further investigate the 4-position and its effects on not only the serotonin receptors but also on other CNS receptors. The serotonergic system is implicated in a plethora of diseases, and gaining a better understanding of target-ligand interactions will optimize future drug design and selectivity and expand our knowledge of how to clinically utilize novel neuromodulators. Experimental Section General Chemistry Information All reactions were performed under argon in heat-dried glassware unless stated otherwise. Controlled-temperature reactions were performed using a sand heat bath. Solvents were removed under reduced pressure using an IKA rotary evaporator. All solvents and reagents were purchased through Thermo Fisher and Oakwood Chemicals. Thin-layer chromatography (TLC) was performed using silica gel F254 glass plates. Detection of UV spots was performed using an Analytik Jena Lamp using both 254/365 nm wavelengths. Flash column chromatography was performed on glass columns using silica gel from Silicycle (230–400 mesh). Low-resolution mass spectra (LRMS) data were obtained on an Agilent LC–MS SQ 6120 (ESI). High-resolution mass spectra (HRMS) data were obtained on an Agilent 6540 series Q-TOF (ESI) and a Shimadzu LC–MS Triple TOF AB Sciex 5600 (ESI). 1H and 13C NMR spectra were obtained using Bruker Neo with Prodigy (400 MHz) and Bruker Neo (600 MHz). Melting points were obtained on an Arco melting point apparatus T2052125/A. The purity of samples tested biologically was determined to be ≥95% by UV. (E)-4-Bromo-3-(2-nitrovinyl)-1H-indole (3) , 4-Br-indole (1.00 g, 7.97 mmol, 1.00 equiv) and 1-(Dimethylamino)-2-nitroethylene (0.926 g, 7.97 mmol, 1.00 equiv) were dissolved in TFA (3.56 mL, 2.24 M) in air. The reaction was stirred for 30 min and was quenched by adding the reaction to a stirred solution of saturated NaHCO3 (100 mL). The resulting slurry was extracted with EtOAc (3 × 50.0 mL), dried over Na2SO4, and concentrated under reduced pressure. The resulting oil was loaded onto silica and purified using column chromatography (gradient: hexanes – 3:1 hexanes:EtOAc) to give the product as a yellow/orange solid (2.06 g, 97%). 1H NMR (DMSO-d 6, 600 MHz) δ 12.58 (br s, 1H), 9.13 (br d, 1H, J = 13.1 Hz), 8.56 (s, 1H), 8.12 (br d, 1H, J = 13.1 Hz), 7.55 (br d, 1H, J = 8.0 Hz), 7.42 (br d, 1H, J = 7.3 Hz), 7.15 (br t, 1H, J = 7.3 Hz); 13C NMR (DMSO-d 6, 151 MHz) δ 138.2, 133.3, 132.1, 131.8, 126.0, 124.0, 123.9, 112.8, 112.6, 107.4. 2-(4-Bromo-1H-indol-3-yl)­ethan-1-amine (4) , (E)-4-Bromo-3-(2-nitrovinyl)-1H-indole (0.268 g, 1.00 mmol, 1.00 equiv) was dissolved in THF (6.56 mL, 0.153 M) and cooled to 0 °C. LiAlH4 (1.00 M, 6.02 mL, 6.02 mmol, 6.00 equiv) was added dropwise to the solution. After the addition was completed, the reaction was warmed to room temperature, then heated to reflux and monitored by TLC. Once the starting material was consumed, as indicated by TLC (0.5 h–1 h), the reaction was removed from heat and cooled to 0 °C. The reaction was quenched with the addition of 3.20 equiv Glauber’s salt, slowly. Once effervescence subsided, the mixture was filtered through a pad of Celite and washed with EtOAc extensively (3 × 100 mL). The filtrate was concentrated under reduced pressure to give the product as an orange solid (0.229 g, 95%). The material was used in the next step without further purification (1.39 g scale; 83%). 2-(4-Bromo-1H-indol-3-yl)-N,N-dimethylethan-1-amine (1) , To a solution of 2-(4-bromo-1H-indol-3-yl)­ethan-1-amine (0.229 g, 0.958 mmol, 1.00 equiv) in ice-cold methanol (6.39 mL, 0.150 M) was added glacial acetic acid (0.270 mL, 4.79 mmol, 5.00 equiv), followed by sodium cyanoborohydride (0.126 g, 2.01 mmol, 2.10 equiv). The mixture was stirred for 5 min. Formaldehyde (37%, 0.200 mL, 2.49 mmol, 2.60 equiv) was added dropwise. The reaction was stirred for 8 h. Upon completion, 15% aq NaOH (5.00 mL) was added to the reaction and the MeOH was removed under reduced pressure. Water (10.0 mL) was added and extracted with CHCl3 (3 × 30.0 mL). The organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was loaded onto silica and purified using column chromatography (gradient: CHCl3 – 10% MeOH/NH3 in CHCl3) to give the product as an off-white solid (0.224 g, 88%). (1.04 g scale; 69%). HPLC purity: 95.7%. Mp 115–117 °C (lit. mp 114–116 °C). 1H NMR (MeOD, 400 MHz) δ 7.31 (d, 1H, J = 8.0 Hz), 7.1–7.2 (m, 2H), 6.93 (t, 1H, J = 7.9 Hz), 3.1–3.2 (m, 2H), 2.6–2.7 (m, 2H), 2.35 (s, 6H); 13C NMR (MeOD, 151 MHz) δ 139.6, 126.5, 125.7, 124.1, 123.1, 114.5, 114.3, 111.9, 63.1, 45.4, 24.9. HRMS (ESI-qToF) calcd for C12H15N2Br ([M + H]+): 266.0419; found, 266.0402. N,N-Dimethyl-2-(4-((trimethylsilyl)­ethynyl)-1H-indol-3-yl)­ethan-1-amine (5) In a reaction vial were added 2-(4-bromo-1H-indol-3-yl)-N,N-dimethylethan-1-amine (84.0 mg, 0.314 mmol, 1.00 equiv), Pd­(PPh3)4 (36.3 mg, 0.0314 mmol, 0.100 equiv), CuI (7.996 mg, 0.418 mmol, 0.133 equiv), and trimethylsilylacetylene (89.5 μL, 0.628 mmol, 2.00 equiv). Degassed triethylamine (1.57 mL, 0.200 M) was added finally, and the vial was flushed with argon before heating to 80 °C. After stirring for 16 h, the reaction was filtered through a pad of Celite and concentrated under reduced pressure. The residue was loaded onto silica and purified using column chromatography (gradient: hexanes – 9:1 EtOAc:hexanes with 2% triethylamine) to give the product (66.6 mg, 75%) as a white oily solid. 1H NMR (CDCl3, 400 MHz) δ 8.85 (br s, 1H), 7.22 (br d, 1H, J = 6.5 Hz), 7.16 (br d, 1H, J = 7.8 Hz), 7.0–7.0 (m, 1H), 6.95 (br s, 1H), 3.2–3.3 (m, 2H), 2.7–2.8 (m, 2H), 2.36 (br s, 6H), 0.28 (br s, 9H); 13C NMR (CDCl3, 101 MHz) δ 136.7, 126.5, 125.6, 123.7, 121.4, 114.8, 113.8, 112.4, 105.5, 96.4, 61.0, 45.4, 23.5, 0.2. HRMS (ESI-triple TOF) calcd for C17H25N2Si ([M + H]+): 285.1781; found, 285.1789. 2-(4-Ethynyl-1H-indol-3-yl)-N,N-dimethylethan-1-amine (6) N,N-Dimethyl-2-(4-((trimethylsilyl)­ethynyl)-1H-indol-3-yl)­ethan-1-amine (41.3 mg, 0.145 mmol, 1.00 equiv) was dissolved in minimal amounts of MeOH in air. K2CO3 (24.1 mg, 0.174 mmol, 1.20 equiv) was added to the solution, and the suspension was stirred for 8 h or until completion as monitored by TLC. The reaction was concentrated under reduced pressure, loaded onto silica, and purified using column chromatography (gradient: CHCl3 – 10% MeOH/NH3 in CHCl3) to give the product (27.9 mg, 91%) as a white solid. Mp 133–135 °C. 1H NMR (CDCl3, 400 MHz) δ 8.48 (br s, 1H), 7.2–7.3 (m, 2H), 7.06 (t, 1H, J = 1.0 Hz), 7.01 (s, 1H), 3.25 (s, 1H), 3.21 (t, 2H, J = 1.0 Hz), 2.67 (t, 2H, J = 1.0 Hz), 2.33 (s, 6H); 13C NMR (CDCl3, 101 MHz) δ 136.8, 127.3, 126.0, 123.7, 121.7, 115.6, 113.3, 112.6, 83.8, 80.0, 61.9, 45.8, 30.0, 24.2. HRMS (ESI-triple TOF) calcd for C14H17N2 ([M + H]+): 213.1386; found, 213.1392. N,N-Dimethyl-2-(4-phenyl-1H-indol-3-yl)­ethan-1-amine (7) 2-(4-Bromo-1H-indol-3-yl)-N,N-dimethylethan-1-amine (50.5 mg, 0.189 mmol, 1.00 equiv), phenyl boronic acid (46.1 mg, 0.378 mmol, 2.00 equiv), Pd2(dba)3 (3.46 mg, 2.00 mol %), XPhos (2.7 mg, 3.00 mol %), and K3PO4 (80.3 mg, 0.378 mmol, 2.00 equiv) were placed in a round-bottom flask under argon. Degassed dioxane (756 μL, 0.250 M) and water (0.151 μL, 1.25 M) were added to the flask. The round-bottom flask was heated to reflux and allowed to stir for 16 h. The reaction was cooled to room temperature and filtered through a pad of Celite. The Celite was washed with EtOAc (3 × 20.0 mL). The filtrate was concentrated under reduced pressure, loaded onto silica, and purified using column chromatography (gradient: CHCl3 – 10% MeOH/NH3 in CHCl3) to give to product as an off-white semi solid (15.4 mg, 32%). 1H NMR (CDCl3, 600 MHz) δ 8.39 (br s, 2H), 7.5–7.5 (m, 2H), 7.45 (br t, 2H, J = 6.9 Hz), 7.40 (br d, 2H, J = 8.0 Hz), 7.23 (t, 1H, J = 1.0 Hz), 7.15 (s, 1H), 6.98 (d, 1H, J = 1.0 Hz), 2.80 (t, 2H, J = 1.0 Hz), 2.25 (t, 2H, J = 1.0 Hz), 2.11 (s, 6H); 13C NMR (CDCl3, 151 MHz) δ 142.0, 137.0, 135.5, 129.5, 127.6, 126.9, 124.3, 123.1, 121.4, 121.3, 114.2, 110.3, 60.4, 44.7, 24.9. HRMS (ESI-triple TOF) calcd for C18H21N2 ([M + H]+): 265.1699; found, 265.1707. Target Profiling: Competition Binding at 5-HTRs See Tables S1 and S2 for assay conditions and other details. Target Profiling: Monoamine Transporter Activities Monoamine transporter assays were performed following previously established procedures. ,, Sprague–Dawley rats were euthanized by CO2 narcosis to obtain fresh brain tissue. For DAT assays, tissue was dissected from the caudate, whereas for NET and SERT assays, whole-brain tissue was collected with the caudate and cerebellum removed. Synaptosomes prepared from these tissue samples were used for both the uptake inhibition and release assays. Tritiated 5-HT, dopamine, and norepinephrine were employed as substrates for the uptake inhibition assays targeting each respective transporter. For SERT release assays, [3H]­5-HT served as the radiolabeled substrate. To calculate the best-fit parameters of interest (IC50, EC50, and E max), three-parameter nonlinear regression analyses were applied to the monoamine transporter assay data. All assays were n = 3 independent experiments, each performed in triplicate. Mouse Studies Briefly, groups of 24 C57BL/6J mice (12 male, 12 female; 8 weeks; Jackson #000664) were housed 4/cage at NIDA IRP (Baltimore) on a 12/12 h light/dark cycle (lights on 6–7 AM). After 1–2 weeks of acclimation, mice were briefly immobilized with isoflurane and implanted subcutaneously with TP500 transponders (Avidity) for noninvasive temperature recording (DAS-8027 IUS). Mice were single-housed postimplantation for the remainder of the experiments. For single drug assays, mice received subcutaneous test drug (0.03–30 mg/kg) or vehicle (saline or 90:5:5 saline:DMSO:Tween 80), and behavior was video-recorded for 30 min (GoPro Hero 10, 11, and 12 cameras; 1080P, 120 fps). For antagonist studies, the protocol was the same, except that mice received an injection of a 5-HT1A antagonist (3 mg/kg of WAY100635) with or without a 5-HT2C antagonist (3 mg/kg of SB242084) prior to 4-Br-DMT. Baseline temperature was recorded after brief chamber acclimation and compared to post-session body temperature readings to obtain temperature change values used. Motor activity (distance traveled) was determined using the head pose-estimation key point, further described below. For video analyses used to determine HTR counts and distance traveled, a DeepLabCut (DLC) pose-estimation model (videos downscaled to 640 × 480, 120 fps via FFmpeg) was trained as recently described. A SimBA classifier (13 body parts; 32 features; pixels/mm set from chamber width; outlier correction skipped) was trained on historical HTR videos not used in DLC training and achieved precision of 95.93, recall of 93.74, and F1 of 94.82 on 38 validation videos (879 HTRs). Hardware/software used: Dell Precision T5820 (Xeon W-2223 3.6 GHz, 32 GB RAM), Windows 11 Pro, NVIDIA RTX A100 GPU; FFmpeg; DLC v2.3.10; SimBA v2.2.4. For data analyses, HTR dose–response curves were visualized with biphasic nonlinear fits, while four-parameter fits were used for motor activity and body temperature change data. HTR potencies were derived from the ascending limb of dose–response curves, and maximal counts (efficacies) were the peak counts observed for each drug. Group comparisons were made via Welch’s ANOVA with Dunnett’s T3 vs vehicle. GraphPad Prism was used for all statistical analyses and figure creation, with alpha set at 0.05 for all comparisons. Psilocin and DMT fumarate were generously provided by the National Institute on Drug Abuse – Drug Supply Program. WAY100635 maleate (item# 14599) and SB242084 HCl (item# 10096) were both purchased from Cayman Chemical (Ann Arbor, Michigan). Supplementary Material